2025
Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients
Yao S, Kocis P, Murphy T, Hwang W. Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients. Pharmacoepidemiology 2025, 4: 6. DOI: 10.3390/pharma4010006.Peer-Reviewed Original ResearchDirect oral anticoagulantsNonvalvular atrial fibrillationNonvalvular atrial fibrillation patientsVitamin K antagonistsSerotonin reuptake inhibitorsHazard ratioBleeding eventsConcomitant useOral anticoagulantsReuptake inhibitorsFollow-upConfidence intervalsElectronic health recordsEstimate hazard ratiosCause-specific proportional hazards modelDOAC prescriptionsHAS-BLED scoreAtrial fibrillation patientsBaseline CHA2DS2-VASc scoreCHA2DS2-VASc scoreRetrospective cohort studyInverse probability of treatmentHealth recordsProportional hazards modelDrug-drug interactionsIntercontinental variations in the presentation and management of venous thromboembolism
Chaar C, Chan S, Lee A, Bikdeli B, Tiberio G, Chopard R, Weinberg I, Yamashita Y, Nikandish R, Monreal M. Intercontinental variations in the presentation and management of venous thromboembolism. JVS-Vascular Insights 2025, 3: 100201. DOI: 10.1016/j.jvsvi.2025.100201.Peer-Reviewed Original ResearchManagement of venous thromboembolismVenous thromboembolismPulmonary embolismLow-risk pulmonary embolismTreatment modalities of patientsOpen pulmonary embolectomyVenous thromboembolism presentationHigh-risk PEIntermediate-risk PELow-molecular-weight heparinLower body mass indexVitamin K antagonistsSystemic thrombolytic therapyProportion of patientsVenous thromboembolism patientsBody mass indexCoronary artery diseaseTreatment of PEPulmonary embolectomyK antagonistsOral anticoagulantsProximal DVTActive cancerOutpatient anticoagulationEndovascular treatmentPerioperative Atrial Fibrillation and Anticoagulation Management
Tao J, Oprea A. Perioperative Atrial Fibrillation and Anticoagulation Management. 2025, 148-161. DOI: 10.1093/med/9780190902001.003.0013.Peer-Reviewed Original ResearchRisk of thrombosisAbstract Atrial fibrillationOral anticoagulantsPreoperative evaluation of surgical patientsCerebral vascular accidentClasses of oral anticoagulantsPatient's risk of thrombosisRisk of surgical bleedingEvaluation of surgical patientsVitamin K antagonistsPerioperative anticoagulation managementK antagonistsSurgical bleedingPreoperative evaluationAnticoagulation managementAtrial fibrillationSurgical patientsCardiac arrhythmiasPatient riskPatientsVascular accidentAnticoagulationRisk
2024
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Fanaroff A, Vora A, Wojdyla D, Mehran R, Granger C, Goodman S, Aronson R, Windecker S, Alexander J, Lopes R. Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. American Heart Journal 2024, 280: 60-69. PMID: 39557109, DOI: 10.1016/j.ahj.2024.11.005.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeTime-to-event analysisAtrial fibrillationCoronary syndromeClinical trialsEffect of antithrombotic therapyVitamin K antagonistsProportion of patientsRobust variance estimationRandomized clinical trialsClinical trial endpointsPercutaneous coronary interventionK antagonistsAntithrombotic therapyPoisson regressionTreatment armsFollow-upIschemic eventsPlaceboRate ratiosAntithrombotic agentsTrial endpointsWarfarinCoronary interventionIntervention methodsEfficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism
Driscoll J, O'Brien S, Newburger J, Mitchell L, Holzhauer S, Ahuja S, Rubio A, Gaitonde P, Robertson A, Polinsky M, Masiukiewicz U, Brandao L. Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism. Blood 2024, 144: 295-295. DOI: 10.1182/blood-2024-198612.Peer-Reviewed Original ResearchDeep vein thrombosisStandard of careLow-molecular-weight heparinVitamin K antagonistsStandard of care groupPulmonary embolismAdverse eventsApixaban groupApixaban concentrationsBleeding eventsPediatric patientsSafety profileIncidence of treatment-emergent adverse eventsLow risk of VTE recurrenceUnfractionated heparinTreatment-emergent adverse eventsRisk of VTE recurrenceStandard of care therapyAge groupsTreatment of venous thromboembolismVTE-related deathSafety of apixabanRecurrent VTE eventsTreatment of VTEMinor bleeding eventsFactor XI: structure, function and therapeutic inhibition
Ali A, Becker R. Factor XI: structure, function and therapeutic inhibition. Journal Of Thrombosis And Thrombolysis 2024, 57: 1315-1328. PMID: 38622277, PMCID: PMC11645426, DOI: 10.1007/s11239-024-02972-5.Peer-Reviewed Original ResearchFactor XI inhibitorsVitamin K antagonistsEnd-stage renal diseaseFactor XITraditional anticoagulantsSafety profileInherent risk of bleedingPhase 3 clinical trialsPhase 2 studyMultiple coagulation factorsRisk of bleedingFactor XI deficiencyIntrinsic pathway of coagulationPathway of coagulationFXI inhibitorsK antagonistsOral anticoagulantsAnticoagulant therapyTherapeutic anticoagulationVenous thromboembolismPreclinical studiesAtrial fibrillationClinical endpointsRenal diseaseClinical trialsComparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation with Factor Xa Inhibitors and Vitamin K Antagonists
Huttler J, Alameddine D, Damara F, Rodriguez P, Wu Z, Slade M, Strosberg D, Ochoa Chaar C. Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation with Factor Xa Inhibitors and Vitamin K Antagonists. Annals Of Vascular Surgery 2024, 104: 185-195. PMID: 38493886, DOI: 10.1016/j.avsg.2023.12.092.Peer-Reviewed Original ResearchVitamin K antagonistsPeripheral arterial diseaseChronic anticoagulationLong-term outcomesFactor Xa inhibitorsAmputation-free survivalK antagonistsXa inhibitorsVitamin K antagonist groupMultivariate logistic regression analysisOutcomes of patientsKaplan-Meier analysisCox proportional hazards regressionLong-term followRate of hematomaProportional hazards regressionPeripheral vascular interventionsLogistic regression analysisOptimal regimenPatient demographicsAnticoagulation regimensVenous thromboembolismAtrial fibrillationFXaIProcedural characteristicsWhen Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, Fanikos J, Connors J, Siegal D, Barnes G, Martin K, Angiolillo D, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind M, Ruff C, Goldhaber S, Krumholz H, Mehran R, Cushman M, Eikelboom J, Lip G, Weitz J, Lopes R, Bikdeli B. When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 444-465. PMID: 38233019, DOI: 10.1016/j.jacc.2023.10.038.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsStandard of careRandomized controlled trialsOral anticoagulantsAtrial fibrillationCatheter-associated deep vein thrombosisCerebral venous sinus thrombosisControlled trialsVitamin K antagonistsThrombotic antiphospholipid syndromeEnd-stage renal diseaseLeft ventricular thrombusVenous thromboembolism treatmentVenous sinus thrombosisDeep vein thrombosisRheumatic heart diseaseReview of randomized controlled trialsEvidence-based reviewK antagonistsAntiphospholipid syndromeSinus thrombosisVentricular thrombusVein thrombosisThromboembolism treatmentVenous thrombosis
2023
Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke
Mac Grory B, Holmes D, Matsouaka R, Shah S, Chang C, Rison R, Jindal J, Holmstedt C, Logan W, Corral C, Mackey J, Gee J, Bonovich D, Walker J, Gropen T, Benesch C, Dissin J, Pandey H, Wang D, Unverdorben M, Hernandez A, Reeves M, Smith E, Schwamm L, Bhatt D, Saver J, Fonarow G, Peterson E, Xian Y. Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA 2023, 329: 2038-2049. PMID: 37338878, PMCID: PMC10282891, DOI: 10.1001/jama.2023.8073.Peer-Reviewed Original ResearchConceptsRisk of sICHSymptomatic intracranial hemorrhageVitamin K antagonistsAcute ischemic strokeSecondary end pointsEndovascular thrombectomyVKA useIschemic strokeHospital mortalityEnd pointIntracranial hemorrhageOral vitamin K antagonistsVitamin K antagonist useGuidelines-Stroke programPrior VKA usePrimary end pointObservational cohort studyLarge vessel occlusionRisk of complicationsAmerican Heart AssociationUse of anticoagulantsSignificant differencesHospital presentationSICH riskAntagonist useComparative Outcomes of Peripheral Vascular Intervention in Patients on Chronic Anticoagulation With Factor Xa Inhibitors and Vitamin K Antagonists
Huttler J, Alameddine D, Damara F, Pinto-Rodriguez P, Wu Z, Slade M, Strosberg D, Chaar C. Comparative Outcomes of Peripheral Vascular Intervention in Patients on Chronic Anticoagulation With Factor Xa Inhibitors and Vitamin K Antagonists. Journal Of Vascular Surgery 2023, 77: e327-e329. DOI: 10.1016/j.jvs.2023.03.453.Peer-Reviewed Original ResearchFactor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealmentDirect Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis
Yaghi S, Saldanha IJ, Misquith C, Zaidat B, Shah A, Joudi K, Persaud B, Khalek F, Shu L, de Havenon A, Mistry EA, Bakradze E, Goldstein ED, Reagan J, Theodorou A, Palaiodimou L, Furie K, Field TS, Tsivgoulis G, Mac Grory B. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke 2022, 53: 3014-3024. PMID: 35938419, DOI: 10.1161/strokeaha.122.039579.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVitamin K antagonistsVenous thrombosisK antagonistsSystematic reviewRelative riskObservational studyDirect Oral Anticoagulants Versus Vitamin K AntagonistsSafety of DOACsVitamin K antagonist treatmentRecurrent venous thromboembolismHigh-level evidenceLeast moderate riskVenous recanalizationOral anticoagulantsVenous thromboembolismMajor hemorrhageMore patientsAntagonist treatmentIntracranial hemorrhageCombination of keywordsComparable efficacyInclusion criteriaSafety outcomesFactor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis
Park D, An S, Arif A, Vij A. Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2022, 40: 82-83. DOI: 10.1016/j.carrev.2022.06.184.Peer-Reviewed Original ResearchApixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke
Bahit M, Vora A, Li Z, Wojdyla D, Thomas L, Goodman S, Aronson R, Jordan J, Kolls B, Dombrowski K, Vinereanu D, Halvorsen S, Berwanger O, Windecker S, Mehran R, Granger C, Alexander J, Lopes R. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke. JAMA Cardiology 2022, 7: 682-689. PMID: 35612866, PMCID: PMC9134037, DOI: 10.1001/jamacardio.2022.1166.Peer-Reviewed Original ResearchConceptsVitamin K antagonistsAcute coronary syndromePercutaneous coronary interventionAtrial fibrillationTransient ischemic attackCRNM bleedingP2Y12 inhibitorsCoronary syndromeAssociated with numerically lower ratesIschemic eventsCoronary interventionEfficacy of apixabanHAS-BLED scoreNumerically lower ratesOral anticoagulant useRate of bleedingRisk of cerebrovascular ischemic eventsHigher CHA2DS2-VAScCox proportional hazards modelsCerebrovascular ischemic eventsAssociated with lower ratesRandomized clinical trialsProportional hazards modelHAS-BLEDK antagonistsImpact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial
Welsh R, Dehghani P, Lopes R, Wojdyla D, Aronson R, Granger C, Windecker S, Vora A, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander J, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart 2022, 9: e001892. PMID: 35172988, PMCID: PMC8852719, DOI: 10.1136/openhrt-2021-001892.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinAtrial FibrillationFactor Xa InhibitorsFemaleHemorrhageHumansIschemiaMaleMedication Therapy ManagementMiddle AgedOutcome and Process Assessment, Health CarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPreoperative PeriodPyrazolesPyridonesVitamin KConceptsOral anticoagulant useVitamin K antagonistsClinically relevant non-major bleedingAcute coronary syndromePercutaneous coronary interventionNon-major bleedingOral anticoagulantsAtrial fibrillationAUGUSTUS trialOral anticoagulation statusElective percutaneous coronary interventionHAS-BLED scoreRisk of myocardial infarctionSecondary analysisHAS-BLEDK antagonistsOpen-labelHigher CHAPrimary endpointAntithrombotic therapyAnticoagulant useClinical outcomesCoronary syndromeIschaemic eventsRandomised treatmentNon-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
Fanaroff A, Vora A, Lopes R. Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. European Heart Journal Supplements 2022, 24: a19-a31. PMID: 35185406, PMCID: PMC8850709, DOI: 10.1093/eurheartj/suab151.Peer-Reviewed Original ResearchNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsValvular heart diseaseRandomized controlled trialsAtrial fibrillationOral anticoagulantsHeart diseaseMitral stenosisControlled trialsBenefits of non-vitamin K antagonist oral anticoagulantsSafety of non-vitamin K antagonist oral anticoagulantsTreated with vitamin K antagonistsManagement of atrial fibrillationMechanical prosthetic mitral valveRheumatic mitral stenosisSevere mitral stenosisMechanical valve prosthesesMechanical prosthetic valvesProsthetic mitral valveK antagonistsStroke prophylaxisConsensus guidelinesMitral valveTranscatheter valvesProsthetic valvesCRT-500.16 Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis
Park D, An S, Arif A, Vij A. CRT-500.16 Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis. JACC Cardiovascular Interventions 2022, 15: s49. DOI: 10.1016/j.jcin.2022.01.203.Peer-Reviewed Original Research
2021
EFFECT OF APIXABAN VERSUS VITAMIN K ANTAGONIST AND ASPIRIN VERSUS PLACEBO ON DAYS ALIVE AND OUT OF HOSPITAL IN THE AUGUSTUS RANDOMIZED CONTROLLED TRIAL
Fanaroff A, Vora A, Wojdyla D, Mehran R, Granger C, Goodman S, Aronson R, Windecker S, Alexander J, Lopes R. EFFECT OF APIXABAN VERSUS VITAMIN K ANTAGONIST AND ASPIRIN VERSUS PLACEBO ON DAYS ALIVE AND OUT OF HOSPITAL IN THE AUGUSTUS RANDOMIZED CONTROLLED TRIAL. Journal Of The American College Of Cardiology 2021, 77: 387. DOI: 10.1016/s0735-1097(21)01746-0.Peer-Reviewed Original Research
2020
Anticoagulation Management in Geriatric Orthopedic Trauma Patients
Morris J, O’Connor M. Anticoagulation Management in Geriatric Orthopedic Trauma Patients. Current Geriatrics Reports 2020, 9: 288-295. DOI: 10.1007/s13670-020-00345-3.Peer-Reviewed Original ResearchDirect oral anticoagulantsOral anticoagulantsAnticoagulation managementGeriatric orthopaedic trauma patientsNon-elective orthopaedic surgeryPerioperative anticoagulation managementRecent FindingsOur understandingHip fracture surgeryVitamin K antagonistsOrthopaedic trauma patientsProthrombin complex concentrateTeam-based approachAnticoagulation interruptionK antagonistsPerioperative anticoagulationPerioperative managementMore patientsTrauma patientsFracture surgeryGeriatric patientsComplex concentrateRegional anesthesiaGeriatric teamReversal agentsOrthopedic surgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply